Infinity Pharmaceuticals, Inc. INFI today announced that new data
for duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase
(PI3K)-delta and PI3K-gamma, will be presented at the American Society of
Hematology (ASH) 2014 Annual Meeting, which is being held December 6-9 in San
Francisco, CA.
Key results to be presented during the meeting include translational data
showing the complementary effects of inhibiting both PI3K-delta and PI3K-gamma
as well as updated data from the Phase 1 study evaluating the safety and
activity of duvelisib in patients with relapsed/refractory indolent
non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic
leukemia (CLL). Updated Phase 1 data on the activity of duvelisib in patients
with T-cell lymphoma will also be reported.
Presentations of duvelisib at ASH 2014 include the following:
Sunday, December 7, 2014, 6:00 p.m. – 8:00 p.m. PT (poster presentation)
Title: Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in
patients with relapsed/refractory chronic lymphocytic leukemia
Abstract Number: 3334
Lead Author: Susan O'Brien, MD, Ashbel Smith Professor and Chief, Section of
Acute Lymphocytic Leukemia in the Department of Leukemia, University of Texas,
M.D. Anderson Cancer Center
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in